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The past few years have seen the development of several
‘‘value frameworks’’ for assessing the relative merits and
prices of cancer drugs, including American Society of
Clinical Oncology’s (ASCO) own value framework.1
These frameworks can have many different aims and
audiences.2,3 For example they may be designed to sup-
port social decisions about value, as in the case of
DrugAbacus.4 ASCO’s framework is designed to support
individual clinical decisions through comparative assess-
ment of treatment alternatives, contemplated as part of
the dialogue between patient and physician.
In this article, we inquire as to whether the ASCO frame-
work can be considered as a valid system for measuring
patient value, and thus for supporting decisions. We con-
trast it with some tools that have been developed by those
within and affiliated with the medical decision-making com-
munity, with a view to making constructive suggestions for
the ongoing development of the framework.
The ASCO Framework as a Tool for Measuring
Value
Value frameworks should produce a score that measures
value in a similar way to the way in which a thermometer
measures temperature. In the ASCO approach, as the
thermometer converts the true temperature to a tempera-
ture reading, the ASCO framework converts the hazard
ratio from a comparative clinical trial to an estimate of a
treatment’s value. But using the hazard ratio for this
purpose poses a challenge, as the ratio says little or noth-
ing about baseline risk, and therefore nothing about the
magnitude of the potential benefit.
Consider the impact of moving from Texas to New
York State, focusing on the change in the risk of death
from car accidents and lightning strikes. The annual mor-
tality risk from car accidents falls from 13.8 to 5.5 per
100,0005; the annual mortality risk from lightning strikes
is about 7.1 per 100 million in Texas and 2 per 100 mil-
lion in New York.6 If one compares the risk reduction,
which is analogous to the hazard ratio, the reduction in
the risk of lightning strikes is nearly 4/10, and the risk
reduction in car accidents is closer to 3/10. This ASCO
framework gives 70 points for the lightning benefit, only
60 for the car fatality benefit, slightly favoring the for-
mer, even though from a lives saved perspective the car
fatality benefit is 1,000 times as large. In other words, the
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framework produces precisely the reverse of what one
would intuitively consider to be more valuable. While
this may seem a made-up example, the problem with rely-
ing on a relative metric finds resonance in oncology
examples—absolute benefits from adjuvant treatment are
routinely larger than those from metastatic treatment,
while the reverse pattern is often seen in their hazard
ratios.
Another feature of the ASCO approach is that a treat-
ment that offers no clinical benefit can actually perform
quite well, due to the fact that toxicity is considered sepa-
rately from the measure of clinical benefit. For instance,
an effective but toxic treatment with a hazard ratio of 17/
20 compared would earn 15 points on the clinical benefit
score. But because having favorable side effects garners
independent points, a piece of candy would actually gar-
ner more points (20), because it has no side effects, even
though it has no benefits either.
Our point is not that patients may have different pre-
ferences for life extension versus toxicity—this is recog-
nized by Schnipper and others1—but rather that it seems
wrong to assign points for nontoxicity independent of
the clinical benefit offered. Comparing cancer treatment
to candy is, of course, absurd, but the reality is that there
are many treatments in oncology that have no or mini-
mal evidence of clinical benefit. If no clinical benefit is
offered, then being nontoxic is not by itself a positive
feature. (This argument is developed more fully in
Morton7.)
Some readers may object that the framework is meant
to be used for the analysis of cancer drugs, not our car-
toon examples. But it is hard to see why we should
believe frameworks that do not give the right answer to
‘‘no-brainer’’ questions (would you prefer to reduce by
50% your mortality risk from a major cause of death
like car accidents or a minor one like lightning strikes?
Would you, as a cancer patient, prefer clinically effective
medicine or clinically ineffective candy?) will give the
right answer in situations where the answers are less
obvious.
Opportunities for Development
Health economics and clinical decision science over the
past few decades have developed several tools for value
measurement.
In health economics, a core concept is the quality-
adjusted life year or QALY.8,9 This is a measure of clini-
cal benefit that measures time alive adjusted for quality.
In Figure 1, for example, we can see and compare two life
trajectories, C and T. It can be seen that T gives longer
life in better quality than C, and the degree of benefit can
be quantified by the dark gray area of the chart between
the two curves.
The QALY is not without its controversies, but it
does capture what people want their medical treatment
to provide, namely, longer life in better health. It expli-
citly incorporates treatment toxicity to the extent that
the toxicity reduces quality of life. In this sense we would
argue that it is a better measure of value than the hazard
ratio.
A focus of life expectancy and health-related quality
of life presupposes that all that matters to the patient in
making a decision is health. But qualitative research has
identified disease burden, alternative available treat-
ments, quality of evidence, and convenience as factors
that are also important when considering treatments.10
In this case, a well-established tool that can be used to
structure such considerations is multicriteria decision
analysis or MCDA.11,12 The basic idea of MCDA is a
simple and familiar one: decision makers can be helped
to analyze complex, multi-attributed choices by compar-
ing the options one attribute at a time, assigning scores
based on each attribute, and weighting and summing the
scores.
The ASCO framework seems to be headed in the
direction of MCDA (in particular it is stated on p. 2931
that the intention is to develop a software tool which will
permit ‘‘weighting by the individual patient’’). However,
experience with MCDA shows that answering clearly
expressed weighting questions in a thoughtful way
requires careful upfront investment in defining the cri-
teria and extensive deliberation in response to the ques-
tions themselves. Hence, a major focus in MCDA
research has been the development of theoretically and
psychologically well-grounded ways to ask for weights,
and the provision of sensitivity analysis that can allow
users to explore their preferences.13,14
Figure 1 The QALY approach to measuring clinical benefit.
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In our view, there is real scope to develop the ASCO
value framework to add more value to the patient-
physician interaction, drawing on the insights from the
health economic and decision science disciplines. For
example, one way to take the ASCO framework forward
would be to replace the Clinical Benefit dimension with
absolute risk reduction, years of life gained or even (if
quality of life data are available), quality-adjusted life
expectancy gains. Additional considerations (e.g., if the
patient feels that it is important that there is treatment-
free interval) could be taken into account using MCDA
methods.
Conclusion
Organizations such as the ASCO have a critical role in
formulating policy around cancer decision making.
However, the ASCO value framework feels like it has
been built ‘‘ground up’’ from data that are available
through clinical trials. Although a natural way to pro-
ceed, we believe that a better and more scientific way to
approach the development of such a framework is to
focus on the decision itself: this means identifying the
core construct that one wants to measure and building a
framework that operationalizes that core concept. This is
likely to revolve around what patients value in terms of
their cancer care and treatment, and this would be con-
sistent with a patient-centric approach to assessing value.
Although evaluating cancer drugs present distinctive
challenges, researchers in health economics and the deci-
sion sciences have produced robust and patient-centered
frameworks to guide decision making. We believe that as
the ASCO framework develops, there is much scope to
learn from this wider body of research in the important
search for value in cancer care.
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